Many Oncology Drugs Approved for Genomic Indications Not Studied for Overall...
There is a lack of survival data for many oncology drugs approved for genomic indications in recent years, according to research published in the European Journal of Cancer. Researchers looked at...
View ArticleDuration of TKI Treatment Predicts Early, Late Recurrence in Chronic Myeloid...
The following article features coverage from the 2021 American Society of Hematology Annual Meeting. Click here to read more of Cancer Therapy Advisor’s conference coverage. The duration of tyrosine...
View ArticleChronic Myeloid Leukemia: 5 Myths You May Encounter
Misconceptions about chronic myeloid leukemia (CML) may present a barrier to treatment. As a clinician, it’s important to remain alert of potential misunderstandings your patients may have. Here are 5...
View ArticlePlatelet, Hemoglobin Levels Related to COVID-19 Mortality in Hematologic...
Low platelet or hemoglobin values may be linked to worse outcomes of COVID-19 for patients with hematologic malignancies, according to results of a retrospective analysis published in Memo – Magazine...
View ArticleClik here to view.
Two-Step Strategy Promising in TKI Dose Reduction in Chronic Myeloid Leukemia
The likelihood of recovery of major molecular response after resuming TKI therapy at reduced doses was 86%. The post Two-Step Strategy Promising in TKI Dose Reduction in Chronic Myeloid Leukemia...
View ArticleClik here to view.
Guidelines for CML Not Followed in the Real World
“Excellent” overall survival is achievable with currently available drugs, according to researchers. The post Guidelines for CML Not Followed in the Real World appeared first on Cancer Therapy Advisor.
View ArticleClik here to view.
Trends in Second Malignancy and Mortality Risk After Primary Chronic Myeloid...
In CML, second malignancies are rare and trends remain poorly understood. The post Trends in Second Malignancy and Mortality Risk After Primary Chronic Myeloid Leukemia appeared first on Cancer...
View ArticleClik here to view.
CML Does Not Affect Antibody Development Against SARS-CoV-2
Investigators reported findings from the ongoing SARS2 SeroPrevalence And Respiratory Tract Assessment (SPARTA) study. The post CML Does Not Affect Antibody Development Against SARS-CoV-2 appeared...
View ArticleClik here to view.
Use of Oral Tyrosine Kinase Inhibitors for R/R CML Increasing Over Time
From 2017 to 2019, the number of beneficiaries prescribed at least 1 oral TKI increased from 154 beneficiaries to 212 beneficiaries. The post Use of Oral Tyrosine Kinase Inhibitors for R/R CML...
View ArticleClik here to view.
Longer Deep Molecular Remission in CML Associated With Treatment-Free Remission
The investigators performed univariate and multivariate analyses to identify factors associated with the loss of MMR. The post Longer Deep Molecular Remission in CML Associated With Treatment-Free...
View ArticleClik here to view.
Asciminib Continues to Demonstrate Superior Efficacy for CML-CP
The patients were randomly assigned 2:1 to asciminib 40 mg twice daily or bosutinib 500 mg once daily. The post Asciminib Continues to Demonstrate Superior Efficacy for CML-CP appeared first on Cancer...
View ArticleClik here to view.
Illegitimate Online Pharmacies May Put Cancer Patients at Risk
Illegitimate online pharmacies are selling imatinib without a prescription, making false claims about being registered with regulatory bodies, and failing to provide patients with drug-related...
View ArticleClik here to view.
Tyrosine Kinase Inhibitor Discontinuation Safe in Pediatric Chronic Myeloid...
Researchers sought to determine if discontinuation of TKI therapy was safe for pediatric patients with CML. The post Tyrosine Kinase Inhibitor Discontinuation Safe in Pediatric Chronic Myeloid...
View ArticleClik here to view.
Utilization Patterns Explain Nonadherence to Treatment for Multiple Myeloma,...
Medicare beneficiaries face unique circumstances that might make medication adherence challenging, and research suggests that many are nonadherent between their first and last fill of their...
View ArticleClik here to view.
PTSD in Cancer Patients: What Providers Need to Know
Cancer survivors are known to be at risk of developing post-traumatic stress disorder (PTSD) related to their illness. Although the prevalence varies across studies and cancer types, PTSD appears to be...
View ArticleClik here to view.
Survey Reveals ‘Striking’ Barriers to Accessing High-Priority Cancer Drugs
An international survey has revealed barriers to accessing cancer drugs deemed essential for routine clinical care. The survey was published in The Lancet Oncology. Researchers surveyed medical...
View ArticleClik here to view.
Algorithm Assesses Risk of Major Adverse Cardiovascular Events in TKI-Treated...
Patients with chronic myeloid leukemia (CML) who are treated with certain tyrosine kinase inhibitors (TKIs) may have a greater risk for adverse cardiovascular events. But healthcare providers do not...
View ArticleClik here to view.
Scemblix Approved for Ph+ Chronic Myeloid Leukemia in Chronic Phase
The Food and Drug Administration (FDA) has granted accelerated approval to Scemblix® (asciminib) for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in...
View ArticleClik here to view.
Comparison of Generic and Branded Imatinib for Patients With Chronic Myeloid...
A recent systematic review of 36 studies suggests that generic imatinib has performed similarly to branded imatinib with regard to efficacy and safety in the treatment of chronic myeloid leukemia...
View ArticleClik here to view.
Factors That Impact HRQOL in Pediatric Patients With Chronic Myeloid Leukemia
Several factors may impact health-related quality of life (HRQOL) in children with chronic phase chronic myeloid leukemia (CML), according to a study published in the Journal of Cancer Research and...
View Article